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Elucidating the antagonistic relationship between Bone Morphogenetic 
Protein and Activin signaling pathways in osteoprogenitor cells 
 
Sylvia Chlebek, Jordan Newby, Jon Arthur, Jonathan W. Lowery  
Division of Biomedical Science, Marian University College of Osteopathic Medicine 
BMP & Activin Signaling Pathways 
Abstract 
Osteoporosis is a disease characterized by low bone mineral density due to the rate of bone resorption 
exceeding that of bone formation. Substantial evidence indicates the Bone Morphogenetic Protein 
(BMP) pathway promotes bone formation through action of the effectors SMAD1/5/8 while the Activin 
pathway negatively influences bone mass through action of the effectors SMAD2/3. Recent studies from 
our lab suggest that BMP and Activin ligands regulate bone mass in a see-saw-like mechanism via 
competition for a shared pool of receptors, i.e. receptor-level competition. In the present study we seek 
to test this hypothesis in vitro via signaling responsiveness assays using pathway-specific western blot 
analyses in the osteogenic cell line W-20-17. We first confirmed that W-20-17 cells respond to 
exogenous stimulation by BMP2 and Activin-A. Then, we administered recombinant versions of 
naturally-occurring extracellular ligand traps for BMP2 or Activin ligands (Noggin and Follistatin, 
respectively) to examine basal antagonism between these pathways. This revealed that, under basal 
conditions, SMAD1/5/8 activation is repressed by Activin signaling; interestingly, the converse 
relationship was not observed. To determine the molecular mechanism allowing for this relationship, we 
treated W-20-17 cells with SB431542, which is an intracellular inhibitor of Activin signaling that functions 
downstream of receptor engagement, and found no effect on SMAD1/5/8 activation. Collectively, our 
results suggest Activin-mediated repression of BMP signaling is ligand-dependent but occurs upstream 
of SMAD2/3 activation. 
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Future direction: ACVR2B overexpression 
Hypothesis 
Increasing the expression level of ACVR2B 
(which is shared by BMP and Activin ligands) 
will alleviate Activin-mediated inhibition of 
BMP signal transduction. 
 
Methods 
cDNA encoding hACVR2B will delivered to 
W-20-17 cells. The expression vector 
contains an C-terminal V5 epitope tag and 
overexpression of hACVR2B will be 
confirmed by western blot. Subsequently, 
control and hACVR2B-overexpressing W-20-
17 cells will be treated with Follistatin and .  
 
Predicted Results 
We predict that overexpression of hACVR2B 
will cause Follistatin treatment to no longer 
increase phosphorylation of SMAD1/5/8 in 
W20 cells. 
Future direction: Inhibition of specific Activin subunits 
Hypothesis 
Sequestering individual Activin subunits will mimic the effect of 
Follistatin on W-20-17 cells. 
 
Methods 
Identify which Activin subunits are endogenously expressed by W-
20-17 cells. Then, deliver neutralizing antibodies against these 
subunits and compare to pan-Activin inhibition by Follistatin. 
 
Predicted Results 
We predict that delivery of anti-Activin-A antibody will mimic the 
effect of Follistatin in W-2-17 cells and lead to increased 




ACVR2A/B modulates signals for the TGF-beta superfamily of ligands, including BMP and Activin. Activin has been shown to counteract 
BMPs that signal through the ACVR2A/B receptors, however, Activin has not been shown to counteract BMPs that signal through 
BMPR2.  
 
Noggin is a BMP-specific antagonist protein, which upon addition to the W-20-17 cells resulted in a decrease in phosphorylation of 
SMAD 1/5/8 and no effect on the phosphorylation of SMAD 2/3. Here we observed that BMP inhibition upstream of the receptor does 
not impact SMAD 2/3 phosphorylation. Such also supports the signaling competency of W-20-17 cells at the basal level, as seen in the 
control group. 
 
Follistatin (FST) is an Activin binding protein, which upon addition to the W-20-17 cells resulted in an increase in the phosphorylation of 
SMAD 1/5/8. Here we observed that Activin inhibition upstream of the receptor allows for the upregulation of BMP signaling. SB-431542 
is an intracellular inhibitor of Activin signaling, which upon addition to the W-20-17 cells resulted in a loss of SMAD 2/3 phosphorylation.  
 
 
Collectively, our data suggest that Activin mediated repression of BMP signaling is ligand dependent 
but occurs upstream of effector activation.  
